Challenges in Pulmonary and Critical Care 2017



COPD – New Management

Outcome Report: Sunovion Grant Med Oncc 116 February 8, 2018





Level 1 (Participation)

Practice

specialty

48% PCPs
15% Hospitalist
6% Pulmonologist
5% Cardiologist
3% Emergency Medicine
23% Other or did not respond





Provide direct patient care



Key Findings



Knowledge/Competence

Improvement in all 4 of the questions addressing the diagnosis and management of COPD, 3 of which achieved statistical significance



Percentage of learners that claimed be somewhat to very confident in their understanding of COPD increased from 35% to 93% four weeks after the program.



91% stated they would implement new strategies learned at this program and 56% stated 4 weeks after program that they had improved their screening protocols for patients with pulmonary disease



Change of Practice Behavior

After 4 weeks, participants reported the following improved skills regarding the treatment of patients with pulmonary disease: 70% disease state awareness, 61% pharmacotherapy, and 48% patient education.

4 Weeks Post N= 164



Discussion and Implications

- Overall, the program improved understanding of the learners in diagnosis and management and pharmacotherapy of COPD
- Major improvement in understanding the disease and its importance
- Learners demonstrated persistent gaps in the several areas including:
 - Selection of stage appropriate inhalers in COPD
 - Complete understanding of trial design and efficacy of approved medications
 - Understanding the phenotypes of COPD

The post-test scores, and intent to change practice patterns regarding the management of patients with chronic obstructive pulmonary disease signifies a clear gap in knowledge and an unmet need among clinicians. It continues to be an important area for future educational programs.



Course Director

Franck Rahaghi, MD, MHS, FCCP Director of Advanced Lung Disease Clinic **Director, Pulmonary Hypertension Clinic** Head of Alpha-1 Foundation Clinical Resource Center Chairman, Dept. of Pulmonary and Critical Care **Cleveland Clinic Florida** Weston, FL

Activity Planning Committee

Gregg Sherman, MD Franck Rahaghi, MD, MHS, FCCP Harvey C. Parker, PhD, CHCP Michelle Frisch, MPH, CHCP Sheila Lucas, CWEP

Faculty

Sajive Aleyas, MD Director, Interventional & Advanced Diagnostic **Bronchology Clinic** Director, Respiratory Center Lung Cancer Program Department of Pulmonary & Critical Care **Cleveland Clinic Florida** Weston, FL

Carmel Celestin, MD Department of Vascular Medicine **Cleveland Clinic Florida** Weston, FL

Frank Eidelman, MD Chair, Department of Allergy & Immunology **Cleveland Clinic Florida** Weston, FL

Anas Hadeh, MD, FCCP Charlie Strange, MD Director, Pulmonary and Critical Care Medicine Professor of Pulmonary and Critical Care Fellowship Program Medicine Affiliate Assistant Professor of Clinical Biomedical Medical University of South Carolina Science Charleston, S FAU Charles E. Schmidt College of Medicine **Cleveland Clinic Florida** Joao A. de Andrade, MD Weston, FL Professor of Medicine

Ileana M. Leyva, MD, FAAHPM **Regional Medical Director** VITAS Healthcare Fort Lauderdale, FL

Jinesh P. Mehta. MD Director, ICU Operations / MICU Pulmonary & Critical Care Medicine **Cleveland Clinic Florida** Weston, FL

Director, Pulmonary Disease and Critical Care Medicine Training Program Director, Interstitial Lung Disease Program University of Alabama at Birmingham Birmingham, AL



Challenges in ^{11th} Annual Symposium Pulmonary & Critical Care 2017

Commercial Support

The Challenges in Pulmonary & Critical Care 2017 held on December 2, 2017 was supported through educational grants or donations from the following companies:

- Actelion Pharmaceuticals US, Inc.
- Bayer Healthcare Pharmaceuticals, Inc.
- Boehringer Ingelheim Pharmaceuticals, Inc.
- CSL Behring
- Grifols
- Mallinckrodt Pharmaceuticals
- Shire
- Sunovion Pharmaceuticals Inc.




Learning Objectives

- 1. Describe strategies of care in COPD to improve diagnosis and ongoing symptom assessment.
- Tailor COPD therapy to the individual patient following current therapeutic strategies accounting for unique patient needs and characteristics, including the appropriate use of inhaled therapeutic devices.
- **3**. Discuss the role of evolving bronchoscopic techniques for lung volume reduction.
- 4. Collaborate with members of interprofessional health care team for to create an effective patient-centered, chronic disease management program.



Levels of Evaluation

Consistent with the policies of the ACCME, NACE evaluates the effectiveness of all CME activities using a systematic process based on Moore's model. This outcome study reaches Level 5.





Level 2 (Satisfaction)







99% indicated the activity improved their knowledge



97% stated that they learned new and useful strategies for patient care



91% said they would implement new strategies that they learned




100% said the program was fair-balanced and unbiased



Attendee Learning Objectives Achievement

Upon completion of this activity, I can now:

- Describe strategies of care in COPD to improve diagnosis and ongoing symptom assessment.
- Tailor COPD therapy to the individual patient following current therapeutic strategies accounting for unique patient needs and characteristics, including the appropriate use of inhaled therapeutic devices.
- Discuss the role of evolving bronchoscopic techniques for lung volume reduction.
- Collaborate with members of interprofessional health care team for to create an effective patient-centered, chronic disease management program.




Sample Size: N = 395



Based on the 2017 update of GOLD guidelines, a patient with an FEV 1 of 70% predicted would be categorized in which GOLD group:

(Learning Objective 1)

P Value: 0.001 – Significant






What COPD phenotype will benefit the most from Phosphodiesterase-4 Inhibitors:

(Learning Objective 2)

P Value: 0.121 – Not Significant






The Flame RCT was a "game changer" as it demonstrated that:

(Learning Objective 2)

P Value: 0.001 – Significant






Which one of the following patients may benefit from referral to a site that is enrolling patients for bronchoscopy volume reduction trial:

(Learning Objective 3)

P Value: 0.001 – Significant




Pre N = 195 Post N = 194



Confidence Assessment

Please rate your confidence in your ability to integrate current and emerging data into the care of your patients with COPD based on disease severity and patient characteristics:





Data Interpretation

More aware of GOLD staging and the importance of multidimensional assessment of COPD rather than relying on spirometry for classification


Are more aware of recent trial data demonstrating efficacy of various inhaler combinations Participant Educational Gains Improved recognition of COPD phenotype that would benefit from Phosphodiesterase-4 Inhibitor therapy

Recognize which patients with COPD are appropriate for lung volume reduction



(4-week Post Assessment N=164)

Please select the specific areas of skills, or practice behaviors, you have improved regarding the treatment of patients with pulmonary disease since this CME activity. (Select all that apply.)





(4-week Post Assessment N=164)

What specific barriers have you encountered that may have prevented you from successfully implementing strategies for patients with pulmonary disease since this CME activity? (Select all that apply)

